Quetiapine in nine youths with autistic disorder

Robert L. Findling, Nora K. McNamara, Barbara L. Gracious, Mary Ann O'Riordan, Michael D. Reed, Christine Demeter, Jeffrey L. Blumer

Research output: Contribution to journalArticle


Objective: The aim of this study was to examine the effectiveness of quetiapine in adolescents suffering from autistic disorder (AD). Methods: This was a 12-week, open-label study, for which medically healthy patients with AD between the ages of 10 and 17 years were eligible. Quetiapine treatment was gradually increased over the first 6 weeks of the study, to a total daily dose of 300 mg/day. Doses could then be increased to a maximum daily dose of 750 mg/day. Outcome measures included the Children's Psychiatric Rating Scale (CPRS) and the Clinical Global Impressions (CGI) scale. Results: Nine (9) males were enrolled. Six (6) patients had previously been treated with other psychotropic agents. Although improvements in several symptom domains were observed on quetiapine, only 2 patients met a priori criteria for response ("much" or "very much improved" on the Clinical Global Impressions- Improvement Scale). In addition, only these same 2 patients' parents/guardians chose to continue quetiapine pharmacotherapy after study participation. Conclusions: These data suggest that quetiapine may not be a particularly effective agent in the treatment of adolescent patients with AD. However, should future studies be performed, it seems reasonable that they be conducted with more rigor, less treatment-resistant cohorts, and, possibly, a different dosing strategy.

Original languageEnglish (US)
Pages (from-to)287-294
Number of pages8
JournalJournal of child and adolescent psychopharmacology
Issue number2
StatePublished - Jun 1 2004


ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Findling, R. L., McNamara, N. K., Gracious, B. L., O'Riordan, M. A., Reed, M. D., Demeter, C., & Blumer, J. L. (2004). Quetiapine in nine youths with autistic disorder. Journal of child and adolescent psychopharmacology, 14(2), 287-294. https://doi.org/10.1089/1044546041649129